Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for ...

CMND-100, a proprietary MEAI-based oral drug candidate, represents a potential breakthrough in AUD treatment, targeting the reduction of alcohol consumption and cravings through a novel mechanism of ...

Lynn Stockwell, the new Chief Executive Officer and Chairman of the Board of Directors of Bright Green Corporation, is also the CEO, Chair and sponsors and manages other NASDAQ listed corporations ...

Additional approximately $21 million tied to data release for the Company’s BEST1 program. RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. ( ...

As previously reported, the LYNX-1 Phase 3 study met its primary endpoint, with a statistically significant greater percentage of Phentolamine Ophthalmic Solution 0.75%-treated participants gaining 15 ...

“This highlights its versatility and effectiveness in addressing critical contamination challenges across diverse industries, including the aquaculture sector. We are excited to continue our ...

Dr. Khoja commented, “Fibroblasts are a critical component of the extracellular matrix with regenerative and immunomodulatory properties. Our presentation will detail the progress we’ve made in ...

Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels. SAN FRANCISCO, March 21, 2025 (GLOBE NEW ...

PharmAla is furthermore pleased to announce that Mr. Ali Taghva will take on new responsibilities, acting as Chief Commercial Officer to the Company, as well as Counsel to the Company. For more ...

Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 In 2023, pharmaceutical companies invested more than EUR 460 million in Finland, half of which ...

Poster underscores Tivoxavir Marboxil’s potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent suppression of resistant viruses and Phase 1 data Full ...

Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today ...